 Biomarker data to be presented provide indication of PrimeCs efficacy in ALS Phase IIb PARADIGM ALS trials primary endpoints include biomarkers and ALS-related hallmarks Topline results expected H1 2023 CAMBRIDGE, Mass. , Sept. 21, 2022 PRNewswire -- NeuroSense Therapeutics Ltd. 